GHK-Cu FDA Status: Compounding and Cosmetics

Start with the name, then check the relevant record. PubChem's copper tripeptide-1 synonyms (opens in a new tab) include GHK-Cu and prezatide copper. These names identify the substance; they do not answer every regulatory question about a product.

For your practice, the review has separate parts: the drug approval search, the exact compounding entry and the product's intended use. Keep those records separate when explaining the status to your team or answering a patient's question.

Is GHK-Cu FDA approved?

No FDA application lists GHK-Cu as an active ingredient, based on the November 4, 2026 Drugs@FDA searches supplied for this review.

The openFDA Drugs@FDA searches checked active ingredients beginning with "ghk" and "prezatide". Both returned no matches. The result supports the answer about an FDA application listing the ingredient. Keep the search terms and date with that answer so the basis for it remains clear.

Compounding is a separate question. In its compounding questions and answers (opens in a new tab), FDA says compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing. An entry in a compounding record should therefore not be described to patients or staff as drug approval.

How does FDA treat GHK-Cu in compounding?

FDA treats the two quoted GHK-Cu compounding entries differently, so your practice should check the exact entry rather than a general statement about the ingredient. FDA's bulk substance safety risk record (opens in a new tab) lists "GHK-Cu (for injectable routes of administration)" among substances previously in 503A category 2 whose nominations were withdrawn. FDA notes immunogenicity risk associated with possible aggregation and peptide-related impurities. It also notes limited human data to inform safety considerations. These are FDA's stated concerns, not administration instructions.

The other entry is "GHK-Cu (except for injectable routes of administration)". FDA's May 14, 2026 document records its return to category 1. The entry had been removed on April 22, 2026 after nominations were withdrawn. On May 5, 2026, one nominator clarified that its withdrawal applied only to the other quoted entry and that it wanted this nomination retained.

Under FDA's section 503A bulk substance framework (opens in a new tab), category 1 means the substance is under evaluation. FDA does not intend to take action against compounders using category 1 substances when the guidance conditions are met. That conditional policy is the relevant distinction when reviewing the category, not the category number alone.

FDA also states that it intends to consult its compounding advisory committee (PCAC) before the end of February 2027 about potential inclusion on the 503A bulks list. An intended consultation is not a completed decision. Separately, GHK-Cu does not appear among the six peptides listed in the HHS policy document (opens in a new tab), which includes Appendix A. Do not treat that draft's list as covering GHK-Cu.

When is a product a cosmetic or a drug?

A product's intended use determines whether it is a cosmetic or a drug; the ingredient name alone does not settle the classification.

The FD&C Act defines cosmetics by their intended use on the body for cleansing, beautifying, promoting attractiveness or altering appearance. This is the general legal definition of a cosmetic.

FDA explains that claims on labeling, in advertising, online or in other promotional materials can make a product a drug, even when it is marketed as a cosmetic. For a practice review, look at the product description and the surrounding claims together. Calling something a cosmetic does not resolve a conflicting intended use expressed in its promotion.

Cosmetic products and ingredients generally do not require FDA approval before marketing, with an exception for color additives. Keep that rule separate from the drug approval question. A cosmetic's lack of a premarket approval requirement is not evidence of an approved drug application. Your review should identify the intended use and claims before drawing a conclusion from the product's category label.

What should a practice check?

Your practice should verify the product's regulatory track, the applicable compounding basis and the claims made about it with your own attorney.

• Identify the track. Separate a cosmetic classification review from a compounded drug review. Record the intended use and relevant labeling. If compounding is involved, match the review to FDA's exact quoted entry and check the conditions attached to the current category.
• Check the 503A basis. Section 503A sets out criteria for bulk drug substances. If an applicable United States Pharmacopeia or National Formulary monograph exists, the substance must comply with it and the applicable compounding chapter. Without such a monograph, the substance must be a component of an FDA-approved drug product or, if it is not, appear on the 503A bulks list. Review category 1's conditional policy separately with your attorney.
• Keep approval language accurate. FDA says compounded drugs should only be used when an FDA-approved drug cannot meet the patient's medical needs. Its lack of premarket verification also matters when reviewing statements about safety, effectiveness or quality. Do not replace that distinction with a general assurance about compounding.
• Examine research labeling in context. In a June 17, 2026 warning letter (opens in a new tab), FDA said "research use only" and "not for human consumption" statements did not prevent it from finding that the products were drugs intended for human use. Review those labels alongside the rest of the product's presentation.
• Check evidence behind claims. The FTC health products guidance (opens in a new tab) says health benefit or safety claims for health-related products require competent and reliable scientific evidence. Ask what evidence substantiates each claim before repeating it in practice materials. A category entry answers a different question from claim substantiation.

For background terminology, see the 503A and 503B comparison guide. Bring the exact product materials, dated FDA entries and proposed practice wording to your own attorney. The useful question is which record supports each statement your practice plans to make.

Related reading

• Are Peptides Legal? FDA Status and Compounding Rules
• Telehealth Regulation News: How to Ensure Virtual Compliance
• How to Pick the Right Medical Spa Lawyer for Your Clinic
• Med Spa Laws by State: Ownership and Licensing

Sources

• FDA: 503A Nominated Bulk Drug Substances (opens in a new tab), checked November 6, 2026.
• FDA: Cosmetic, Drug or Both? (opens in a new tab), checked November 6, 2026.
• PubChem: Copper Tripeptide-1 Synonyms (opens in a new tab), checked November 6, 2026.
• FDA: Compounding Questions and Answers (opens in a new tab), checked November 6, 2026.
• FDA: Bulk Substance Safety Risks (opens in a new tab), checked November 6, 2026.
• FDA: Bulk Substances Under Section 503A (opens in a new tab), checked November 6, 2026.
• HHS: Draft 503A Peptide Enforcement Policy (opens in a new tab), checked November 6, 2026.
• FDA: June 17, 2026 Warning Letter (opens in a new tab), checked November 6, 2026.
• FTC: Health Products Compliance Guidance (opens in a new tab), checked November 6, 2026.